Design, synthesis, and evaluation of novel 6-chloro-/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 5, 2006, Pages 1366-1370

  Ishar, M P S ^a   Singh, Gurpinder ^a   Singh, Satyajit ^b   Sreenivasan, K K ^b   Singh, Gurmit ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

^b MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Anticancer; Antitumor; Chromone; DNA topoisomerases; Topoisomerase inhibitors

Indexed keywords

6 CHLORO 2 MORPHOLINO 4 YL 3 FORMYLCHROMONE; 6 CHLORO 2 N METHYLPIPERAZIN 1 YL 3 FORMYLCHROMONE; 6 CHLORO 2 PIPERIDIN 1 YL 3 FORMYLCHROMONE; 6 CHLORO 2 PYRROLIDIN 1 YL 3 FORMYLCHROMONE; 6 FLUORO 2,7 BIS(N METHYLPIPERAZIN 1 YL) 3 FORMYLCHROMONE; 6 FLUORO 2,7 DIMORPHOLINO 4 YL 3 FORMYLCHROMONE; 6 FLUORO 2,7 DIPIPERIDIN 1 YL 3 FORMYLCHROMONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; EHRLICH ASCITES TUMOR; ELECTROSPRAY MASS SPECTROMETRY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CHROMONES; DNA TOPOISOMERASES; DRUG DESIGN; ENZYME INHIBITORS; MICE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE;

ANIMALIA;

EID: 31444457188     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.044     Document Type: Article

References (48)

1. J. Champaux J.C. Wang N.R. Cozarelli DNA Topology and Its Biological Effects 1990 Cold Spring Harbor Laboratory Cold Spring Harbor, NY 217
2. T.-S. Hsieh J.C. Wang N.R. Cozarelli DNA Topology and Its Biological Effects 1990 Cold Spring Harbor Laboratory Cold Spring Harbor, NY 243
3. M. Caserta, A. Amadei, G. Camilloni, and E. Di Mauro Biochemistry 29 1990 8152
4. F.G. Harrnon, R.J. DiGate, and S.C. Kowalczykowski Mol. Cell 3 1999 611
5. M. Nagarajan, A. Morrell, B.C. Fort, M.R. Meckley, S. Antony, G. Kholhagen, Y. Pommier, and M. Cushman J. Med. Chem. 47 2004 5651
6. Y. Pommier, and A. Tanizawa J. Hickman T. Tritton Cancer Chemotherapy 1993 Blackwell Scientific Publications Oxford 214
7. A.U. Chen, and L.F. Liu Annu. Rev. Pharmacol. Toxicol. 94 1994 194
8. M. Zewail-Foote, and L. Hurley Anti-Cancer Drug Des. 14 1999 1
9. C. Levine, H. Hiasa, and K.J. Marians Biochim. Biophys. Acta 1400 1998 29
10. Potmesil, M., Kohn, K. K (Eds.), Topoisomerases in Cancer, Oxford University Press: New York, 1991, Chapter 2.
11. N. Osheroff Pharmacol. Ther. 41 1989 223
12. J. Spicer, G. Finlay, B. Baguley, L. Velea, D. Graves, and W. Denny Anti-Cancer Drug Des. 14 1999 37
13. T.D. Gootz, and K.E. Birghty V.T. Andriole The Quinolones 2nd ed. 1998 Academic Press San Diego 29
14. D.C. Hooper Clin. Infect. Dis. 32 2001 S9
15. J.-Y. Fan, D. Sun, H. Yu, S.M. Kerwin, and L.H. Hurley J. Med. Chem. 38 1995 408
16. G.S. Laco, W. Du, G. Kohlhagen, J.M. Sayer, D.M. Jerina, T.G. Burke, D.P. Curran, and Y. Pommier Biorg. Med. Chem. 12 2004 5225
17. G. Cianchetta, R. Mannhold, G. Cruciani, M. Baroni, and V. Cecchetti J. Med. Chem. 47 2004 3193
18. Y.-H. Hsiang, R. Hertzberg, S. Hecht, and L.F. Liu J. Biol. Chem. 260 1985 14873
19. S.B. Mhaske, and N.P. Argade J. Org. Chem. 69 2004 4563
20. M. Nagarajan, X. Xiao, S. Antony, G. Kohlhagen, Y. Pommier, and M. Cushman J. Med. Chem. 46 2003 5712
21. M.E. Wall Med. Res. Rev. 18 1998 299
22. G.M. Cragg, and D.J. Newman J. Nat. Prod. 67 2004 232
23. N. Osheroff, E.L. Zechiedrich, and K.C. Gale BioEssays 13 1991 269
24. N.J. Rahier, B.M. Eisenhauer, R. Gao, S.H. Jones, R.G. Shannon, and S.M. Hecht Org. Lett. 6 2004 321
25. P. Arimondo, C. Boukarim, C. Bailly, D. Dauzonne, and C. Monneret Anti-Cancer Drug Des. 15 2000 413
26. Z. Xiao, J.R. Vance, K.F. Bastow, A. Brossi, H.-K. Wang, and K.-H. Lee Bioorg. Med. Chem. Lett. 12 2004 3363
27. J.M. Cassady, W.M. Baird, and C.J. Chang J. Nat. Prod. 53 1990 23
28. S.M. Kupchan, D.R. Streelman, and A.T. Sneden J. Nat. Prod. 43 1980 296
29. M.Y. Kim, Y. Na, H. Vankayalapati, and M. Gleason-Guzman J. Med. Chem. 46 2003 2958
30. Y. Kwok, D. Sun, J. Clement, and L. Hurley Anti-Cancer Drug Des. 14 1999 443
31. J.M. Domagala J. Antimicrob. Chemother. 33 1994 685
32. A. Bryskier, and J.-F. Chantot Drugs 49 Suppl. 2 1995 16
33. T.D. Gootz, and K.E. Brighty Med. Res. Rev. 16 1996 433
34. Y. Xia, Z.-Y. Yang, P. Xia, T. Hackl, E. Hamel, A. Mauger, J.-H. Wu, and K.-H. Lee J. Med. Chem. 44 2001 3932
35. M.P.S. Ishar, K. Kumar, and R. Singh Tetrahedron Lett. 39 1998 6547
36. G. Singh, R. Singh, N.K. Girdhar, and M.P.S. Ishar Tetraherdon 58 2002 2471
37. G. Singh, L. Singh, and M.P.S. Ishar Tetraherdon 58 2002 7883
38. Spectroscopic and microanalytical data
39. EAC was obtained from Radiobiology Department, Kasturba Medical College, Manipal, India, and was propagated by serial transplantation in Swiss Albino mice in Central Animal Facility at Manipal Academy of Higher Education, Manipal, India.
40. M. Gupta, U.K. Mazumder, R.S. Kumar, and T.S. Kumar Acta Pharmacol. Sin. 25 2004 1070
41. A. Bhattacharyya, T. Choudhuri, S. Pal, S. Chattopadhyay, G.K. Datta, G. Sa, and T. Das Carcinogensis 24 2003 75
42. Cisplatin was used as standard at 3.5 mg/kg.
43. 21a as % ILS = Median Survival Time (MST) ÷ MST of Control group × 100.
44. Glutathione level has been determined by literature protocol [(a) Lowry, O. H.; Roesebrough, N. J.; Farr, A. L.; Randall, R. J. J. Biol. Chem. 1951, 193, 265.
45. (b) Moron, M. S.; Depierre, J. W.; Mannervik, B. Biochim. Biophys. Acta 1979, 5820, 62].
46. One-way analysis of variance (ANOVA) with Dunnet's test was applied to all data.
47. K. Yagi Chem. Phys. Lipids 45 1991 337
48. A.J. Sinclair, A.H. Barnett, and J. Lunie Br. J. Hosp. Med. 43 1990 334